MedTrace Logo

Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

NCT04570501 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-03-03

No results posted yet for this study

Summary

The primary objective is to evaluate the safety and efficacy of intravenous (IV) infusion of Ang (1-7) compared to placebo with respect to time to recovery, disease severity, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and mortality in patients with COVID 19.

Conditions

  • Covid19

Interventions

DRUG

Angiotensin-(1-7)

Ang (1-7) administered by continuous intravenous (IV) infusion

DRUG

Placebo

Placebo (normal saline) administered by continuous intravenous (IV) infusion

Sponsors & Collaborators

Principal Investigators

  • Kevin V Grimes, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2022-08-31
Completion
2022-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04570501 on ClinicalTrials.gov